Home › Therapeutic areas › Immunology

Immunology (57 companies · 22 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Immunology Lead stage Mkt cap Programs
ABVX Abivax Immunology 2 Phase 3 $7.19B 2
ACET Adicet Bio ImmunologyNeurology+2 Rare 5 Phase 1 $26.0M 8
ADMA Adma Biologics ImmunologyInfectious Disease Rare 2 Approved $3.02B 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $292M 4
ALLO Allogene Therapeutics ImmunologyOncology Rare 3 Phase 2 $256M 10
ALMS Alumis DermatologyImmunology+1 3 Phase 3 $628M 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved $1.36B 9
RCUS Arcus Biosciences DermatologyImmunology+1 1 Phase 3 $2.36B 8
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.93B 4
CABA Cabaletta Bio DermatologyImmunology+2 Rare 5 Phase 2 $220M 8
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 2 Phase 3 $187M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 4 Phase 3 $2.20B 6
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 6 Phase 1 $249M 9
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 2 Phase 2 $13.2M 4
CLYM Climb Bio HematologyImmunology+1 Rare 2 Phase 2 $574M 8
CUE Cue Biopharma ImmunologyOncology 2 Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 4 NDA Submitted $602M 10
DBVT DBV Technologies Immunology 2 NDA Submitted $3.14B 2
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 1 Phase 2 $167M 3
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 1 Approved $253M 8
EVMN Evommune DermatologyImmunology+1 3 Phase 2 $290M 6
FATE Fate Therapeutics ImmunologyOncology+1 Rare 4 Phase 2 $124M 10
IMVT Immunovant ImmunologyNeurology Rare 2 Phase 3 $6.87B 4
INAB IN8bio ImmunologyOncology 1 Phase 1 $8.9M 4
INSM Insmed CardiovascularImmunology+3 Rare 1 Approved $26.7B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare 1 NDA Submitted $1.37B 3
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $4.49B 29
JBIO Jade Biosciences ImmunologyRenal Rare 2 Phase 2 $1.07B 4
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 1 Phase 2 $10.4B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
LQDA Liquidia CardiovascularImmunology+1 Rare 1 Approved $5.11B 9
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 1 Phase 3 $827M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 0 Approved $1.54B 5
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $47.7M 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $775M 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 2 NDA Submitted $957M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
NKTX Nkarta ImmunologyNeurology+1 Rare 5 Phase 1 $89.6M 8
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
ORKA Oruka Therapeutics DermatologyImmunology Rare 1 Phase 2 $6.53B 7
PTN Palatin Technologies ImmunologyMetabolic+1 1 Phase 3 $9.5M 5
PALI Palisade Bio Immunology 2 Phase 2 $181M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 2 Phase 2 $4.8M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 3 Approved $8.14B 12
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 1 Phase 2 $236M 4
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved $236M 4
SEPN Septerna ImmunologyMetabolic+1 Rare 3 Phase 1 $1.90B 5
SYRE Spyre Therapeutics DermatologyImmunology Rare 9 Phase 2 $8.91B 10
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $822M 7
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $83.2M 5
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
VRDN Viridian Therapeutics ImmunologyOphthalmology 2 Approved $3.41B 7
VOR Vor Biopharma ImmunologyNeurology Rare 1 Phase 3 $1.12B 2
XNCR Xencor ImmunologyNeurology+1 Rare 10 Approved $2.59B 28
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted $1.88B 11
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 $99.7M 4